Document Detail

Human skeletal dysplasia caused by a constitutive activated transient receptor potential vanilloid 4 (TRPV4) cation channel mutation.
Jump to Full Text
MedLine Citation:
PMID:  23143559     Owner:  NLM     Status:  MEDLINE    
The transient receptor potential vanilloid 4 (TRPV4) cation channel, a member of the TRP vanilloid subfamily, is expressed in a broad range of tissues where it participates in the generation of Ca²⁺ signals and/or depolarization of the membrane potential. Regulation of TRPV4 abundance at the cell surface is critical for osmo- and mechanotransduction. Defects in TRPV4 are the cause of several human diseases, including brachyolmia type 3 (MIM:113500) (also known as brachyrachia or spondylometaphyseal dysplasia Kozlowski type [MIM:118452]), and metatropic dysplasia (MIM:156530) (also called metatropic dwarfism or parastremmatic dwarfism [MIM:168400]). These bone dysplasia mutants are characterized by severe dwarfism, kyphoscoliosis, distortion and bowing of the extremities, and contractures of the large joints. These diseases are characterized by a combination of decreased bone density, bowing of the long bones, platyspondyly, and striking irregularities of endochondral ossification with areas of calcific stippling and streaking in radiolucent epiphyses, metaphyses, and apophyses. In this review, we discuss the potential effect of the mutation on the regulation of TRPV4 functions, which are related to human diseases through deviated function. In particular, we emphasize how the constitutive active TRPV4 mutant affects endochondral ossification with a reduced number of hypertrophic chondrocytes and the presence of cartilage islands within the zone of primary mineralization. In addition, we summarize current knowledge about the role of TRPV4 in the pathogenesis of several diseases.
Sang Sun Kang; Sung Hwa Shin; Chung-Kyoon Auh; Jaesun Chun
Related Documents :
3159469 - Dysfunction of calcium handling by smooth muscle in hypertension.
12642509 - Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential h...
3430689 - Intralymphocytic sodium and free calcium concentration in relation to salt sensitivity ...
2993039 - Relationships among endogenous digitalis-like factors in essential hypertension.
3049099 - Mechanism of action of calcium antagonists in heart and vascular smooth muscle.
15071349 - Gene expression and functional activity of sodium/calcium exchanger enhanced in vascula...
6782889 - Electrical stimulation of the liver cell: activation of glycogenolysis.
3000429 - Ca2+-dependent cyclic nucleotide phosphodiesterase is activated by poly(l-aspartic acid).
7994849 - Marked activation delay caused by ischemia initiated after regional k+ elevation in in ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Experimental & molecular medicine     Volume:  44     ISSN:  2092-6413     ISO Abbreviation:  Exp. Mol. Med.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-14     Completed Date:  2013-05-20     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  9607880     Medline TA:  Exp Mol Med     Country:  Korea (South)    
Other Details:
Languages:  eng     Pagination:  707-22     Citation Subset:  IM    
Department of Biology Education Chungbuk National University Cheongju 361-763, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Osteochondrodysplasias / genetics*
Osteogenesis / genetics
TRPV Cation Channels / chemistry,  genetics*,  metabolism
Reg. No./Substance:
0/TRPV Cation Channels; 0/TRPV4 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Exp Mol Med
Journal ID (iso-abbrev): Exp. Mol. Med
Journal ID (publisher-id): EMM
ISSN: 1226-3613
ISSN: 2092-6413
Publisher: Korean Society for Biochemistry and Molecular Biology
Article Information
Download PDF
Copyright © 2012 by the Korean Society for Biochemistry and Molecular Biology
Accepted Day: 29 Month: 9 Year: 2012
Print publication date: Day: 17 Month: 12 Year: 2012
Electronic publication date: Day: 08 Month: 11 Year: 2012
Volume: 44 Issue: 12
First Page: 707 Last Page: 722
PubMed Id: 23143559
ID: 3538978
DOI: 10.3858/emm.2012.44.12.080

Human skeletal dysplasia caused by a constitutive activated transient receptor potential vanilloid 4 (TRPV4) cation channel mutation
Sang Sun Kang1
Sung Hwa Shin1
Chung-Kyoon Auh3
Jaesun Chun2
1Department of Biology Education, Chungbuk National University, Cheongju 361-763, Korea.
2Department of Biology Education, Korea National University of Education, Cheongwon 363-791, Korea.
3Department of Biological Science, Mokpo National University, Muan 534-729, Korea.
Correspondence: Corresponding author: Tel, 82-43-261-3278; Fax, 82-43-271-0526;


The transient receptor potential vanilloid 4 (TRPV4) cation channel, a member of the TRP vanilloid subfamily, is expressed in a broad range of tissues, where it contributes to the generation of a Ca2+ signal and/or the depolarization of membrane potential (Vennekens et al., 2008; Everaerts et al., 2010; Verma et al., 2010; Lewis et al., 2011; Chun et al., 2012). TRPV4 is a polymodal Ca2+-permeable cation channel of 871 amino acid (Delany et al., 2001; Watanabe et al., 2002b). It shows a very prominent outward rectification, rarely opening upon hyperpolarization (Voets et al., 2005; Loukin et al., 2010a). Mutational analyses suggest that outward rectification is governed by a gating mechanism independent of the main intracellular gates (Kim et al., 2010; Loukin et al., 2010a).

The predicted TRPV4 structure harbors six membrane-spanning domains with a pore loop, an N-terminal domain with at least three ankyrin repeats, and a C-terminal domain residue within the cytoplasm (Delany et al., 2001; Watanabe et al., 2002b; Voets et al., 2005; Loukin et al., 2010a). These characteristics are common features in all six TRPVs (TRPV1-6) (Vennekens et al., 2008; Everaerts et al., 2010; Chun et al., 2012). Although the TRPV family shows similar characteristics, each member has its own distinguishable functions from other TRPVs (Figure 1).

The participation of TRPV4 in osmo- and mechanotransduction is relevant to several important functions, including cellular and systemic volume homeostasis, arterial dilation, nociception, bladder voiding, and the regulation of ciliary beat frequency (Suzuki et al., 2003b; Andrade et al., 2005; Becker et al., 2005; Earley et al., 2005; Birder et al., 2007; Hartmannsgruber et al., 2007). TRPV4 channel activity can be sensitized by the co-application of a variety of stimuli and by the participation of a number of cell signaling pathways, which suggests the presence of different regulatory sites (Nilius et al., 2004; Shin et al., 2012). In this regard, several proteins have been proposed to modulate TRPV4 subcellular localization and/or function, including microtubule-associated protein 7, calmodulin, F-actin, and pacsin3 (Strotmann et al., 2003; Suzuki et al., 2003a; Cuajungco et al., 2006; Ramadass et al., 2007); (Table 1). A functional and physical interaction between inositol trisphosphate receptor 3 and TRPV4 has been demonstrated, which sensitizes the latter to the mechano- and osmotransducing messenger, 5'-6'-epoxieicosatrienoic acid (Vriens et al., 2005; Fernandes et al., 2008). TRPV4 is also responsive to temperature, endogenous arachidonic acid metabolites, and phorbol esters, including 4-α phorbol 12, 13-didecanoate (4-αPDD), and participates in receptor-operated Ca2+ entry, thus, possessing multiple activation modes (Guler et al., 2002; Watanabe et al., 2003; Jia et al., 2004); (Table 2). However, the precise manner in which TRPV4 is regulated in the cell by these protein interactions, chemicals, and stimuli remains to be clearly elucidated.

Many mammalian cell types, including renal tubule cells, bronchial epithelia, keratinocytes, spermatocytes, and erythrocytes, encounter varying osmolarities in their environments (Strotmann et al., 2000; Vriens et al., 2004). The ability of these cells to adapt to changing osmotic conditions is critical for cellular homeostasis, and disequilibria can result in dramatic events, including apoptosis and necrosis. Therefore, a variety of cell types have evolved specialized mechanisms for volume regulation to counteract the damage induced by either swelling or shrinking of cells (Alessandri-Haber et al., 2003; Vriens et al., 2004). Under hypotonic conditions, cells increase their volume via water uptake mediated by the osmotic gradient. The reduction in volume to its former value is achieved by a process referred to as regulatory volume decrease (RVD), which allows cells to survive in a hypotonic environment. The direct participation of TRPV4 in RVD at the cellular level and systemic osmosensing in organisms has been demonstrated (Becker et al., 2005).

Although TRPV4 mutants develop several genetic bone diseases, including brachyolmia type 3 (BRAC3) [MIM:113500]; also known as brachyrachia and spondylometaphyseal dysplasia Kozlowski type (SMDK) [MIM:184252], and metatropic dysplasia (MTD) [MIM:156530]; also called metatropic dwarfism or parastremmatic dwarfism (PSTD) [MIM:168400], only abnormal osmotic regulation in TRPV4-/- mouse has been reported (Suzuki et al., 2003b; Verma et al., 2010; Kang, 2012); (Figure 2 and Table 3). It is currently unclear why the phenotype of TRPV4-/- mice is so much different than that of TRPV4 point mutants. The TRPV4 knockout mouse phenotype does not fully recapitulate any of the human phenotypes under discussion but bladder dysfunction and hearing loss have been reported (Tabuchi et al., 2005; Gevaert et al., 2007). Defects in TRPV4 are the cause of several human diseases including BRAC3 [MIM:113500]; also known as brachyrachia or SMDK [MIM:184252], and MTD [MIM:156530]; also called metatropic dwarfism or PSTD [MIM:168400] (Auer-Grumbach et al., 2010; Dai et al., 2010; Deng et al., 2010; Landoure et al., 2010; Verma et al., 2010; Kang, 2012; McEntagart, 2012). These bone dysplasia mutants are characterized by severe dwarfism, kyphoscoliosis, distortion and bowing of the extremities, and contractures of the large joints (Figure 3 and Table 3). These diseases are characterized by a combination of decreased bone density, bowing of the long bones, platyspondyly, and striking irregularities of endochondral ossification with areas of calcific stippling and streaking in radiolucent epiphyses, metaphyses, and apophyses (Kang, 2012; McEntagart, 2012).

Thus, in this review, the potential effect of the mutation on the regulation of TRPV4 functions is discussed, which is related to the bone diseases through its deviated function and how the mutant TRPV4 affects endochondral ossification, with reduced numbers of hypertrophic chondrocytes and the presence of cartilage islands within the zone of primary mineralization (Figure 4). With the analysis of TRPV4 mutants, we noticed the tendency that human skeletal dysplasia is caused by a constitutive activated TRPV4 mutation, but not by a constitutive inactivated mutation (Figure 5). We also realized that the seriousness of disease is dependent on its channel activity. In addition, the current knowledge about the role of TRPV4 in the pathogenesis of skeletal dysplasia is summarized (Figure 2 and Table 3).

Naturally occurring TRPV4 mutants and genetic bone disorders

Few naturally occurring TRPV4 mutants have been identified. Interestingly, most of these missense and nonsense point mutations are linked with the development of genetic disorders in humans and a detailed list of naturally occurring TRPV4 mutations and related disease has been documented (Figure 2 and Table 3). Some of these mutations that have gained importance in terms of genetic disease had been discussed (Verma et al., 2010; Kang, 2012; McEntagart, 2012).

BRAC3 [MIM:113500]

BRAC3 was characterized using a linkage analysis and candidate gene sequencing. Rock et al. (2008) found that some patients affected with brachylomia have a TRPV4 missense mutation, specifically at positions R616Q or V620I, respectively (Auer-Grumbach et al., 2010; Dai et al., 2010; Deng et al., 2010; Landoure et al., 2010). These mutations are located at the fifth transmembrane region, which is a part of the functional pore. Each of these mutations increases basal level activity when compared to that of wild-type TRPV4 (TRPV4-WT). Additionally the response to 4-αPDD (a TRPV4 specific agonist) is greater in the mutants when compared with that in the WT. This result also indicates that these two mutations preferably stabilize TRPV4 in its "open stage" resulting in constitutive activity of the channel. BRAC3 constitutes a clinically and genetically heterogeneous group of skeletal dysplasias characterized by a short trunk, scoliosis, and mild short stature. BRAC3 is an autosomal dominant form, and patients have severe kyphoscoliosis and flattened, irregular cervical vertebrae (Loukin et al., 2011).

BRAC3, caused by the R616Q gain-of-function channel, possesses increased whole-cell current densities compared with those of WT channels (Loukin et al., 2011). A single-channel analysis revealed that R616Q channels maintain mechano sensitivity but have greater constitutive activity and no change in unitary conductance or rectification. The BRAC3 range from mild autosomal-dominant BO (brachylomia), diagnosed by a shortened spine with characteristic vertebral defects and minor defects in the long bones to MTD characterized by more prominent spine defects as well as pronounced abnormalities in the articular skeleton resulting in short dumbbell-shaped long bones, which lead to prenatal lethality in its severest form (Loukin et al., 2010b; Lamande et al., 2011; Nemec et al., 2012). The reason why TRPV4 R616Q (which shows greater constitutive activity and no change in unitary conductance or rectification) causes such a prominent phenotype is unknown.

MTD [MIM:156530]

MTD is a clinical heterogeneous skeletal dysplasia characterized by short extremities, a short trunk with progressive kyphoscoliosis, and craniofacial abnormalities including a prominent forehead, midface hypoplasia, and a squared-off jaw (Krakow et al., 2009; Camacho et al., 2010). Dominant mutations in the gene encoding TRPV4 were identified in all 10 of a series of MTD cases, ranging in severity from mild to perinatal lethal. MTD is a severe spondyloepimetaphyseal dysplasia characterized by short limbs with limitation and enlargement of joints and severe kyphoscoliosis (Cho et al., 2012). Radiologic features include severe platyspondyly, severe metaphyseal enlargement, and shortening of long bones (Andreucci et al., 2011). TRPV4 I331F and P799L mutations are well known to induce MTD (Krakow et al., 2009; Camacho et al., 2010). As all these mutants are naturally occurring and are not embryonically lethal (as most lethal mutants may be naturally excluded from the population). Notably, none of these mutants show complete loss of their prime function, i.e., ionic conductivity (Krakow et al., 2009; Cho et al., 2012).

Several experimental results suggest that some of these mutants even have enhanced channel opening. Furthermore, they demonstrate that the lethal form of the disorder is dominantly inherited and suggest locus homogeneity in the disease (Krakow et al., 2009; Camacho et al., 2010; Andreucci et al., 2011; Cho et al., 2012). Additionally, electrophysiological studies have demonstrated that the mutations activate the channel, indicating that the disease mechanism may result from increased calcium in chondrocytes (Camacho et al., 2010). Histological studies in two cases of lethal MTD revealed markedly disrupted endochondral ossification with a reduced number of hypertrophic chondrocytes and the presence of cartilage islands within the zone of primary mineralization. These data suggest that altered chondrocyte differentiation in the growth plate leads to the clinical findings of MTD (Krakow et al., 2009; Camacho et al., 2010; Andreucci et al., 2011; Cho et al., 2012).

Distal spinal muscular atrophy congenital non-progressive (DSMAC) [MIM:600175]

DSMAC (also called hereditary motor and sensory neuropathy, type IIC; HMSN2C) is a clinically variable, neuromuscular disorder characterized by a congenital lower motor neuron disorder restricted to the lower part of the body (Auer-Grumbach et al., 2010; Deng et al., 2010; Ding et al., 2010). Clinical manifestations include non-progressive muscular atrophy, thigh muscle atrophy, weak thigh adductors, weak knee and foot extensors, minimal jaw muscle and neck flexor weakness, flexion contractures of the knees, and pes equinovarus. However, tendon reflexes are normal (Deng et al., 2010; Nilius and Owsianik, 2010; Zimon et al., 2010).

Inheritance is autosomal dominant. The R315W mutation has been identified in an unrelated family that also had HMSN2C. Auer-Grumbach et al. discovered two additional TRPV4 mutations (R269H and R316C) in affected members of three additional families with these three phenotypes, indicating that they are allelic disorders (Auer-Grumbach et al., 2010; Zimon et al., 2010). All three mutations occurred at the outer helices of the ANK4 and ANK5 domains in the N-terminal cytoplasmic domain (Figure 2). In vitro functional expression studies in HeLa cells have shown that the mutant protein forms cytoplasmic aggregates and has reduced surface expression, as well as an impaired response to stimulus-dependent channel activity. These results suggest that the mutations interfere with normal channel trafficking and function. Furthermore, Auer-Grumbach et al. identified a different heterozygous mutation in the TRPV4 gene (R315W) in a patient with congenital distal SMA whose other family members with the same mutation had phenotypes consistent with hereditary motor and sensory neuropathy-2 or scapuloperoneal spinal muscular atrophy; thus, proving that these are allelic disorders with overlapping phenotypes (Auer-Grumbach et al., 2010; Deng et al., 2010; Nilius and Owsianik, 2010; Zimon et al., 2010).

Spondyloepiphyseal dysplasia Maroteaux type (SEDM) [MIM:184095]

SEDM is a clinically variable spondyloepiphyseal dysplasia with manifestations limited to the musculoskeletal system (Dai et al., 2010; Loukin et al., 2011). Clinical features of SEDM include short stature, brachydactyly, platyspondyly, short and stubby hands and feet, epiphyseal hypoplasia of the large joints, and iliac hypoplasia, even though patient intelligence is normal (Andreucci et al., 2011). Genetic mapping of the patients affected with this disease shows a missense mutation in TRPV4 of either E183K, Y602C, or E797K (Krakow et al., 2009; Camacho et al., 2010; Dai et al., 2010; Loukin et al., 2011). The channel activity of the TRPV4 E797K mutant in HEK293 cells is constitutively active, which is consistent with the argument that effects on TRPV4 are the cause of SEDM. It is a clinically variable spondyloepiphyseal dysplasia with manifestations limited to the musculoskeletal system. Both SEDM and parastremmatic dysplasia are part of the TRPV4 dysplasia family, and TRPV4 mutations show considerable variability in phenotypic expression resulting in distinct clinical-radiographic phenotypes (Krakow et al., 2009; Camacho et al., 2010; Andreucci et al., 2011).

PSTD [MIM:168400]

Defects in TRPV4 are also the cause of PSTD, which is a bone dysplasia characterized by severe dwarfism, kyphoscoliosis, distortion and bowing of the extremities, and contractures of the large joints (Andreucci et al., 2011). This disease is radiographically characterized by a combination of decreased bone density, bowing of the long bones, platyspondyly, and striking irregularities of endochondral ossification with areas of calcific stippling and streaking in radiolucent epiphyses, metaphyses, and apophyses (Andreucci et al., 2011; Nemec et al., 2012).

Nishimura et al. (2010) analyzed the candidate TRPV4 gene in a 7-year-old girl with PSTD and identified heterozygosity for a missense mutation (R594H) that had previously been found in patients with the Kozlowski type of SMDK (Nishimura et al., 2010). However, in patients with the Kozlowski type of SMDK, Krakow et al. (2009) identified a 1781G-A transition in exon 11 of the TRPV4 gene, resulting in an arg594-to-his (R594H) substitution in the cytoplasmic S4 domain (Krakow et al., 2009). Thus, both PSTD and SMDK, which are caused by the TRPV4 mutation, seem to be associated with increased basal intracellular calcium ion concentration and intracellular calcium activity. However, the Kozlowski type of SMDK is different from SEDM in the TRPV4 mutation sites (E183K Y602C, or E797K).

Charcot-Marie-Tooth disease type 2C (CMT2C) and scapuloperoneal spinal muscular atrophy (SPSMA) [MIM:606071]

CMT2C is an axonal form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system that is characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms (Deng et al., 2010; Landoure et al., 2010). Charcot-Marie-Tooth disease is classified into two main groups based on electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy (Bird, 1993; Nilius and Owsianik, 2010). Nerve conduction velocities are normal or slightly reduced. CMT2C and SPSMA are also known as hereditary motor and sensory neuropathy type 2 (Chen et al., 2010; Landoure et al., 2010). Patients with SPSMA are characterized by weakness of the scapularis muscle and bone abnormalities. CMT2C leads to weakness of distal limbs and vocal cords and often impairs hearing and vision. Genetic analyses of these patients have shown the presence of TRPV4 missense mutations, particularly at the R269H, R315W, and R316C positions (Bird, 1993; Deng et al., 2010; Landoure et al., 2010).

Familial digital arthropathy-brachydactyly (FDAB)

FDAB is a dominantly inherited condition characterized by aggressive osteoarthropathy of the fingers and toes and consequent shortening of the middle and distal phalanges (Amor et al., 2002). Lamandé et al. showed that FDAB is caused by mutations encoding p.Gly270Val, p.Arg271Pro, and p.Phe273Leu substitutions in the intracellular ankyrin-repeat domain of the TRPV4 cation channel (Lamande et al., 2011). The TRPV4 mutant in HEK-293 cells showed that the mutant proteins have poor cell-surface localization. Those authors also suggested that TRPV4 mutations that reduce channel activity cause a third phenotype, inherited osteoarthropathy, which shows the importance of TRPV4 activity in particular cartilage homeostasis. Thus, the TRPV4 mutant (G270V, R271P, and Y273L) also seems to be related with FDAB (Nilius and Owsianik, 2010; Verma et al., 2010; Kang, 2012; McEntagart, 2012; Nemec et al., 2012).

Other diseases (not included bone) with TRPV4 mutations
Serum sodium level quantitative trait locus (hyponatremia)

Tian et al. (2009) demonstrated that the rs3742030 single nucleotide polymorphism in the TRPV4 gene (P19S) is significantly associated with serum sodium concentration (Tian et al., 2009). After this discovery, hyponatremia was defined as serum sodium < 135 mEq/L in non-Hispanic Caucasian male populations. In heterologous expression studies in HEK293 cells, P19S mutant channels show a diminished response to hypotonic stress and to the osmotransducing lipid epoxyeicosatrienoic acid compared to that in WT channels (Carreno et al., 2009; Nedungadi et al., 2012). The P19S polymorphism affects TRPV4 function in vivo and likely influences systemic water balance on a population wide basis.

Chronic obstructive pulmonary disease (COPD)

COPD is characterized by airway epithelial damage, bronchoconstriction, parenchymal destruction, and mucus hypersecretion (Zhu et al., 2009; Li et al., 2011). Upon activation by a broad range of stimuli, TRPV4 functions to control airway epithelial cell volume and epithelial and endothelial permeability; it also triggers bronchial smooth muscle contraction and participates in autoregulation of mucociliary transport (Obeidat et al., 2011). These TRPV4 functions may be important for regulating COPD pathogenesis; thus, TRPV4 is a candidate COPD gene. The TRPV4 P19S mutant, which is characterized as the cause of the hyponatremia, is also observed in COPD.

Fetal akinesia

Recently, Unger et al. reported that the fetal akinesia as the presenting feature of severe metatropic dysplasia, was identified as a certain TRPV4 mutant which can cause both a skeletal and a neuropathic phenotype (Unger et al., 2011). Three cases were detected on prenatal ultrasound because of absent movements in the second trimester. The mutation of TRPV4 were confirmed the presence of de novo heterozygous mutations predicting G78W, K276E, and T740I (Figure 2 and Table 3).

The TRPV4 regulatory mechanism

The gating diversity of the TRPV4 channel demonstrated in the current study reflects the presence of multiple physical and chemical signaling pathways that converge on the channel regardless of the mechanism (Vennekens et al., 2008; Everaerts et al., 2010; Lewis et al., 2011; Chun et al., 2012). As a consequence, the TRPV4 channel appears to function as a molecular integrator of a complex array of diverse signals (Tables 1 and 2). Because multiple environmental signals and transduction pathways converge on TRPV4, the channel may function as a molecular integrator of microenvironmental chemical and physical signals. Further study to elucidate the TRPV4 regulation mechanism is required to clearly determine the physiological role and mechanism of channel activation (Delany et al., 2001; Voets et al., 2002; Watanabe et al., 2002b; Loukin et al., 2010a).

The Ser 824 residue of TRPV4 is localized within its F-actin or microtubule-binding domain (798-809 amino acids) of TRPV4 (Suzuki et al., 2003a; Shin et al., 2012). Consequently, the functional relevance of Ser 824 residue phosphorylation in the context of cytoskeletal interaction should be emphasized (Suzuki et al., 2003a; Lee et al., 2010; Chun et al., 2012; Shin et al., 2012). Thus, phosphorylation of the TRPV4 Ser 824 residue exerts a regulatory effect on its functional Ca2+ entry, protein stability, and its interactions with CaM (Figures 1 and 3), F-actin or microtubules result in an expansion of cell surface area and proper subcellular localization (Suzuki et al., 2003a; Chun et al., 2012; Shin et al., 2012).

TRPV4 channel activation and serine phosphorylation are enhanced by exposure to the non-PKC activator 4-α PDD or by applying bradykinin, which activates protein kinase C (PKC) or PKA via a G-protein-coupled mechanism. This enhancement was inhibited by the PKC inhibitors staurosporine, BIM, and rottlerin, and by mutation of the serine/threonine residues S162, T175, and S189 (Table 2). Enhancement of TRPV4 activity by S824 phosphorylation is expected to be agonized or antagonized by the selective SGK1 activity modulators (IGF2 and wortmannin) (Lee et al., 2010). However, basal activity and sensitivity to 4-α PDD of TRPV4 S824A (an analog of unphosphorylated TRPV4 by SGK1) was higher than those of the TRPV4 WT, suggesting that the TRPV4 C-terminal domain near the serine residue 824 was assigned to regulate its function by an unknown controlling mechanism beyond the phosphorylation modification, such as a protein-protein interaction with CaM (Amor et al., 2002; Strotmann et al., 2003; Chun et al., 2012). Because the TRPV4 Ser824 residue has also been detected in the consensus SGK1 substrate sequences, whether or not SGK1 phosphorylates the Ser 824 residue of TRPV4, as one of its specific substrate proteins was ascertained (Figure 1 and Table 2). SGK1-mediated phosphorylation of the TRPV4 Ser 824 residue exerts a synergistic effect on functional Ca2+ entry, as well as reactivity to 4-α PDD, interactions with CaM, subcellular localization, and cell survival (Figures 1 and 2).

TRPV4 is modulated by phosphorylation of a Ser824 residue negative/positive feedback regulation loop. In a short-term regulation loop (Figure 3), TRPV4 WT appears to be dually modulated by the association of regulatory proteins (such as Ca2+ bound CaM) on its C-terminal cytoplasmic domain (Figure 1). First, the naive TRPV4 begins to open in response to several over-threshold environmental signals (e.g., mechanical chemical, temperature, and osmolality). TRPV4 is positively activated by dissociation with regulatory proteins such as CaM at low Ca2+ concentrations. However, the channel is negatively feedback inhibited at high Ca2+ concentrations by the fully active TRPV4 and returned to the inactive form; these mechanisms constitute the short-term negative/positive feedback regulation loop (Figure 3). This phenomenon also explains our observation that TRPV4 WT shows Ca2+ ion concentration oscillations in the cytoplasm after activation with 4-α PDD or heat. In contrast, after the TRPV4 WT is phosphorylated on its Ser824 residue by SGK1, the prolonged active (phosphorylated) form (a TRPV4 S824D analogue), which remains active until being dephosphorylated on its Ser824 residue by a protein phosphatase and the association of a putative regulatory protein (such as Ca2+-CaM). Consistent with this assumption, TRPV4 S824D (an analogue with a prolonged active form), shows high Ca2+ channel activity with/without 4-α PDD treatment, abrogating the protein interaction with the inhibitory factor (Amor et al., 2002; Strotmann et al., 2003; Chun et al., 2012). This model explains why the TRPV4 E797 mutant is constitutively active. Following 4-α PDD or heat treatment, TRPV4 S824A appears to be analogous with its active form. TRPV4 S824A, which is not associated with the inhibitory protein Ca2+-CaM (as an inhibition complex) returns back to an inactive form (Figure 3). This may explain why channel activity and Ca2+ entry of TRPV4 S824A appear to be higher than those of TRPV4 WT after 4-α PDD treatment. However, binding of Ca2+-CaM can be prevented by SGK1-mediated phosphorylation of a serine 824 residue within the CaM binding site.

Conversely, substitution of the target site (serine 824) with aspartic acid (S824D) results in a more rapid and longer activation of TRPV4-mediated currents, as Ca2+-CaM binding can be prevented by phosphorylation (Amor et al., 2002; Chun et al., 2012; Shin et al., 2012). This convergence on a shared C-terminal domain may represent an important mechanism by which the timing and convergence of signal responses is controlled. Although Ca2+-CaM as the negative feedback regulator at high Ca2+ concentration is the focus of this research, binding competition with other proteins on the TRPV4 C-terminal region cannot be ruled out (Figure 3). It seems to be valuable to elucidate the protein that interacts with the C-terminal region of TRPV4.

TRPV4 harbors a consensus sequence for protein-Ser 824 phosphorylation by SGK1 within the putative CaM, actin, or tubulin binding domain (811-850 amino acids). Thus, Ca2+-CaM binding is modified by phosphorylation on Ser 824. In this regard, the CaM binding site on its C-termini seems to be involved in Ca2+-induced conformational changes. It is likely that the Ser 824 of the C-terminal domain induces a conformational change in the TRPV4 channel protein that results in decreased (or inactivated) channel activity, as both TRPV4 S824D, and S824A (such as the TRPV4 E797 mutant regardless of phosphorylation) are more active than that of TRPV4 WT (Amor et al., 2002; Shin et al., 2012).

A variety of stimuli activate members of the various TRPV subfamilies. Vanilloid compounds such as capsaicin, the compound responsible for the spiciness of hot chili peppers, moderate heat, and protons activate TRPV4 channels and function as integrators of a variety of painful stimuli. Furthermore, TRPV4 is sensitive to noxious heat and can be constitutively activated by growth factors (Table 2).

The nitric oxide (NO) donor induces S-nitrosylation at Cys853 in the C terminus of TRPV4. S-nitrosylation at the Cys853 residue in the TRPV4 channel functionally and directly regulates channel sensitivity. We propose that NO conversely inhibits the Ca2+ response and direct S-nitrosylation on the Cys853 of TRPV4 as negative feedback regulation (Ding et al., 2010; Lee et al., 2011). Endothelial NO synthase and TRPV4 co-localize in the caveolar fraction of guinea pig hearts, thereby indicating close proximity of the NO donor and the target protein (Yoshida et al., 2006). Thus, multiple factors are responsible for making the Cys853 of TRPV4 (a target of molecule-specific and site-specific S-nitrosylation). Although TRPV5 and TRPV6 are tightly controlled by membrane potential, including a voltage-dependent open-pore block by Ca2+-dependent feedback mechanism, it is unknown whether TRPV4 is also regulated in the same manner. S-nitrosylation of the TRPV4 channel seems to be a Ca2+-dependent feedback mechanism (Figure 3). S-nitrosylation of native TRPV4 upon G protein-coupled ATP receptor stimulation elicits Ca2+ entry into endothelial cells (Yoshida et al., 2006; Ding et al., 2010). In the case of TRPV4, however, even though the increase of NO in cells also appears to enhance S-nitrosylation of native TRPV4, the nitrosylation site (C853) of TRPV4 is located in its C-terminal tail, and Ca2+ transport by the channel appears to be inactivated by this modification, as a negative feedback Ca2+ transport regulation mechanism. However, the fully active TRPV4 is inhibited by negative feedback at high Ca2+ ion levels and returned to the inactive form, as a negative feedback regulatory loop by NO (S-nitrosylation). Therefore, the channel properties of TRPV4 are similar those of voltage-gated Na+ channels. The various modifications of the TRPV channel C-terminal are summarized in Table 2.

The mode of action of TRPV4 mutants

The mode of action of the mutations in these TRPV4-related disorders has proved difficult to elucidate. Initial functional work investigating the impact of the mutations seen in the neuropathy group was conflicting, as both gain-of-function and loss-of-function mechanisms were proposed (Figures 4 and 5). This may have resulted from different experimental protocols, as each group studied different cell lines (HEK293, HeLa, Xenopus oocytes, and dorsal root ganglion cells). Further work by Fecto et al. investigated three of the TRPV4 neuropathy spectrum mutations in three cell types (HEK293, HeLa, and Neuro2a cells) and proposed that they caused the channels to have an increased channel open probability and an increased sensitivity to agonists (4α-PDD) (Fecto et al., 2011). They suggested that this observation could have resulted from a change in channel gating or increased membrane insertion of the channels (Deng et al., 2010; Fecto et al., 2011). Cell viability studies have shown a correlation with increased calcium influx and cytotoxicity that could be reversed by a TRPV4 channel inhibitor (ruthenium red; (Watanabe et al., 2002a)). Interestingly Loukin et al. studied 14 of the skeletal dysplasia-associated TRPV4 mutations in Xenopus oocytes and found evidence for increased open probability of the mutant channels (Loukin et al., 2010a; Loukin et al., 2011). Mutant channels also show increased sensitivity to channel agonists (4α-PDD and hypotonicity). They observed a correlation between increasing levels of channel open probability and phenotype severity (Loukin et al., 2010a; Loukin et al., 2011). Hence, mutations that result in the mildest phenotype, brachyolmia, cause an approximate 2% increase in channel open probability, whereas open probability of mutant channels causing the severe phenotype MTD approached 100%. TRPV4 participates in terminal differentiation of developing osteoclasts by providing sustained calcium influx, but the mechanism by which these mutations cause the skeletal dysplasia remains unclear (Figure 4). Finally, functional studies of the TRPV4 mutations causing FDAB in HEK293 cells showed a small increase in channel open probability with a slight increase in sensitivity to channel agonists and reduced cell surface expression. The overall effect was thought to result in a reduction in channel activity (Figures 4 and 5).

The effects of these mutations on other factors such as protein folding, post translational glycosylation, protein-protein interactions, heterotetramerization, and protein trafficking may also contribute to the phenotypic expression of these TRPV4 mutations (Cuajungco et al., 2006; Wang et al., 2007; Fernandes et al., 2008; Ma et al., 2011). Consideration of the three-dimensional structure of the channel reveals that four key residues in the ARD (ankyrin repeat domains) (Table 3) associated with the neuropathy spectrum are surface mutations, not thought to affect protein folding. They cluster on the positively charged convex surface of the ARD and involve highly conserved arginine residues, whereas the skeletal dysplasia mutations affecting the ARD are situated on the concave surface and may interrupt the protein-protein interactions (Hellwig et al., 2005; Arniges et al., 2006). Thus, the mutations in each group of conditions may affect different protein functions, while overlapping conditions may result from mutations affecting residues involved in shared functions of the protein. TRPV4 forms homotetramers, but recent work has shown that it interacts with other channels including TRPC1 and TRPP2, forming heterotetramers with a 2:2 stoichiometry and alternating subunit arrangement results in distinct electrophysiological properties (Hellwig et al., 2005; Feng et al., 2011).

Further work has shown that TRPV4 interacts with the cytoskeleton and regulates microtubules and actin, which, in turn, is regulated by microtubule dynamics (Suzuki et al., 2003a; Ramadass et al., 2007; Shin et al., 2012). Thus, the full effects of the TRPV4 mutations may result from effects on additional functions of the protein not just on changes to the channel gating properties. Further studies are required to elucidate the pathogenic mechanisms occurring in these disorders and identify the genetic and environmental modifying factors that cause such striking variation in disease expression.

Conclusion and perspective

The TRPV4 functional Ca2+ channel consists of the homo tetramer subunits. TRPV4 and TRPC1 can co-assemble to form heteromeric TRPV4-C1 channels (Hellwig et al., 2005; Feng et al., 2011). Because the TRPV4 ankyrin repeat is responsible for channel self-assembly in cell lines, mutations in the TRPV4 ankyrin domain also seem to affect the channel assembly in humans, as shown in many dominant negative genetic disorders (Hellwig et al., 2005; Arniges et al., 2006).

TRPV4 was originally shown to be activated by hypotonicity, but later studies have demonstrated that activation can also be achieved by phorbol esters, arachidonic acid, and moderate heat (Guler et al., 2002; Watanabe et al., 2002a; Alessandri-Haber et al., 2003; Watanabe et al., 2003; Vriens et al., 2004; Birder et al., 2007). TRPV4 appears to be an important player in pathological sensory perception and bone growth. The potential effect of a TRPV4 functional mutation remains to be elucidated in the future. Furthermore, the role of TRPV4 in the pathogenesis of several diseases should be characterized as to how the channel protein contributes to the specific diseases. This information may be useful to cure or alleviate the human disease caused by TRPV4 mutations.

As expected, TRPV4 activation in osteoclasts increased the number of osteoclasts and their resorption activity, thereby resulting in bone loss. During in vitro analysis, TRPV4R616Q/V620I osteoclasts showed activated Ca2+/calmodulin signaling compared with osteoclasts lacking TRPV4 (Mizoguchi et al., 2008; Rock et al., 2008; Everaerts et al., 2010). In addition, studies in TRPV4R616Q/V620I mice, which lack the calmodulin-binding domain, indicate that bone loss due to TRPV4 activation was abrogated by loss of interactions between Ca2+/calmodulin signaling and TRPV4. Finally, modulators of TRPV4 interactions with the calmodulin-binding domain should be investigated by proteomic analysis (Tables 1 and 2).

Bones are constantly undergoing remodeling to adapt to mechanical stress, repair (micro) fractures, and regulate mineral metabolism (Mizoguchi et al., 2008; Abed et al., 2009; Masuyama et al., 2012). Mechanical stress plays an important role in bone formation and remodeling. Importantly, mechanical unloading of bones leads to the suppression of bone formation and increases bone resorption, as observed in bedridden patients that develop osteoporosis (Mizoguchi et al., 2008; Everaerts et al., 2010). As TRPV4 is expressed in both osteoblasts (responsible for bone deposition), and osteoclasts (mediate bone resorption), it may play a role in sensing mechanical stress and controlling bone remodeling (Mizoguchi et al., 2008; Abed et al., 2009; Masuyama et al., 2012). In mice, mechanical hind limb unloading induces osteopenia, reduces bone formation rate, and stimulates bone resorption by increasing the number of osteoclasts. In contrast, these effects are suppressed in TRPV4-/- mice (Mizoguchi et al., 2008). Moreover, TRPV4-/- mice show mild osteopetrosis, increased trabecular bone mineral density and increased cortical thickness, resulting from reduced bone resorption as a consequence of disrupted osteoclast differentiation (Figure 4). TRPV4-mediated Ca2+ influx plays a crucial role in Ca2+-dependent regulation of nuclear factor-activated T cells c1 (NFATc1), a transcription factor that controls osteoclast-specific gene expression (Masuyama et al., 2008).

TRPV4 in chondrocytes of cartilage tissue is involved in modulating chondrogenic bone formation by regulating sex determining region Y-box 9 (SOX9) activity (Muramatsu et al., 2007). SOX9 is a well-established chondrocyte transcription factor that regulates expression of cartilage-specific extracellular matrix proteins and controls chondrocyte differentiation and bone formation (Figure 4). TRPV4 stimulates SOX9-dependent reporter activity in mesenchymal stem cells via a Ca2+-calmodulin dependent mechanism. The role of TRPV4 requires further elucidation in the case of late chondrogenic differentiation, in which SOX9 functions as a negative regulator. Thus, it seems that TRPV4 mutants, which are constitutively active, maintain Ca2+ influx and its high concentration, resulting in activated NFATc1. As a consequence, osteoclast-specific gene expression is enhanced. The eventual phenotype of those mutants appears like SEDM (Figures 4 and 5 and Table 3).

Recent observations on endothelial cells (ECs) indicate that small numbers of EC TRPV4 channels regulate vascular physiology and suggest that pathologies characterized by blood pressure reduction and vascular permeability increases (e.g., septic shock) may involve excessive activation of EC TRPV4 channels (Sonkusare et al., 2012). These results demonstrate that a small number of active TRPV4 channels (about three to eight per cell) mediate local Ca2+ signals that activate the intermediate (IK)- and the small (SK)-conductance, Ca2+-sensitive potassium (K+) channels to cause maximal dilation of resistance arteries. Similarly, in the chondrocyte, osteoblast, or osteoclast a small number of active TRPV4 channels mediate local Ca2+ signals that activate other channel such as IK and SK (Sonkusare et al., 2012). Even the increased ATP binding in E183K and E278K also contribute to constitutive TRPV4 activity, and the increase in TRPV4 activity seems to lead to TRPV4-linked spinal disease phenotypes (Phelps et al., 2010; Inada et al., 2012). Thus, the mutant TRPV4 channel that has increased activity in bone cells compared to normal causes a catastrophic effect, such as BRAC3, CMT2C, MTB, PSTD, or SEDM (Figures 4 and 5 and Table 3).

However, FDAB is not same as SEDM, because FDAB TRPV4 (G270V, R271P, Y273L) is not constitutively active compared to that of the TRPV4 WT. The mutation sites of FDAB TRPV4 are localized between ankyrin repeats 3 and 4, which seem to be responsible for membrane localization. FDAB is caused by mutations encoding p.Gly270Val, p.Arg271Pro, and p.Phe273Leu substitutions in the intracellular ankyrin-repeat domain of the TRPV4 cation channel. The TRPV4 mutant that causes FDAB is poorly localized to the cell-surface in HEK-293 cells and shows reduced channel activity (Amor et al., 2002; Dai et al., 2010; Lamande et al., 2011; Loukin et al., 2011). Therefore, it is assumed that the TRPV4 mutant causes the different phenotypic diseases, depending on mutant TRPV4 channel activity (Figure 5). The balance between osteoblasts and osteoclasts seems to be regulated by TRPV4 activity (Figure 4). The only ambiguous mutant is the G806A (exon 5) mutation which causes both SMA/HMSN2C and CMT2C (Table 3). It is not clarified yet that the channel activity of TRPV4 R269H is constitutively active or not (Amor et al., 2002; Dai et al., 2010; Lamande et al., 2011; Loukin et al., 2011). It is not obvious why some mutations result in one phenotype over another but an intriguing possibility is that certain mutations associated with the neurological phenotype may predispose the TRPV4 transcript to act like no other TRPV isoform (trans-speciation) (Dai et al., 2010; Nishimura et al., 2010). Recent evidence also suggests that the mutations associated with a skeletal phenotype caused the increased calcium channel basal activity (Loukin et al., 2010a; Loukin et al., 2010b; Loukin et al., 2011). However, the same has been shown for mutations associated with the clear neurological phenotype (Deng et al., 2010; Fecto et al., 2011).

TRPV4 should be the first line of genetic investigation in any individual presenting with a predominant motor axonal neuropathy. Documentation of height and any skeletal complaints should also be determined. Those providing genetic counseling for these families need to be aware of the frequent occurrence of non-penetrance and the striking phenotypic variability (Bird, 1993; Dai et al., 2010). The importance of identifying the correct hereditary neuropathy subtype may have moved beyond prognostication and genetic counseling, as there is no treatment for these disorders, but the existence of known agonists and antagonists of the TRPV4 channel have prompted many suggestions that therapeutic pharmacological modification of the mutant channels may be possible.

Even though it is not completely accorded in all mutant cases yet, the mutant shown the more channel activity than the TRPV4 WT causes the abnormality of backbone morphogenesis (cause BRAC3, CMT2C, MTB, PSTD or SEDM), whereas the mutant shown the less channel activity than the TRPV4 WT causes the abnormality of articular morphogenesis or the neuropathy (FDAB or HMSN2C) (Figures 2 and 5 and Table 3). TRPV4 mutants are constitutively active and maintain high Ca2+ influx, resulting in activated NFATc1 and high osteoclast-specific gene expression (Wegierski et al., 2006). Thus, TRPV4 mutant causes the different phenotypic diseases, depending on the mutant TRPV4 channel activity. In addition, the balance of cell number between osteoblast and osteroclast seems to be regulated by the TRPV4 activity.

Several mutants studied in heterologous expression systems show constitutive basal activity and enhanced response to stimuli (Deng et al., 2010; Loukin et al., 2010a; Fecto et al., 2011; Loukin et al., 2011). These findings are consistent with cell death caused by high calcium influx such as the observed degeneration of motor neurons in neuropathies. However, it is difficult to explain how seemingly similar molecular properties lead to such diverse disease phenotypes. It is essential to elucidate how TRPV4 is regulated at the molecular level to understand the mechanisms behind these inherited diseases.

Further studies are required to understand the pathogenic mechanisms occurring in these disorders and identify the modifying genetic and environmental factors that cause such striking variation in disease expression. The reason why TRPV4 mutations, which show greater constitutive activity and no change in unitary conductance or rectification, cause such prominent spinal diseases will be elucidated. Further, among 26 members of the TRP subfamily which are expressed in a broad range of tissues, why the only TRPV4 cation channel contributes to the generation of such many genetic bone diseases should be answered.


This work was supported by National Research Foundation of Korea (NRF) grants (2009-0076024 and 2009-0069007) funded by the Korea government (MEST) to S S Kang. We also appreciated The Core Facility of Chungbuk National University.

BRAC3 brachyolmia type 3
CMT2C Charcot-Marie-Tooth disease type 2C
COPD chronic obstructive pulmonary disease
DSMAC distal spinal muscular atrophy congenital non-progressive
FDAB familial digital arthropathy-brachydactyly
HEK293 cells human embryonic kidney 293 cells
HMSN2C hereditary motor and sensory neuropathy, type IIC
MIM mendelian inheritance in man
MTD metatropic dysplasia
PSTD parastremmatic dwarfism
SEDM spondyloepiphyseal dysplasia Maroteaux type
SMA spinal muscular atrophies
SMDK spondylometaphyseal dysplasias Kozlowski type
SPSMA scapuloperoneal spinal muscular atrophy
TRP transient receptor potential
TRPV vanilloid receptor-related TRPs

1. Abed E,Labelle D,Martineau C,Loghin A,Moreau R. Expression of transient receptor potential (TRP) channels in human and murine osteoblast-like cellsMol Membr BiolYear: 20092614615819115145
2. Alessandri-Haber N,Yeh JJ,Boyd AE,Parada CA,Chen X,Reichling DB,Levine JD. Hypotonicity induces TRPV4-mediated nociception in ratNeuronYear: 20033949751112895423
3. Amor DJ,Tudball C,Gardner RJ,Lamande SR,Bateman JF,Savarirayan R. Familial digital arthropathy-brachydactylyAm J Med GenetYear: 200210823524011891693
4. Andrade YN,Fernandes J,Vazquez E,Fernandez-Fernandez JM,Arniges M,Sanchez TM,Villalon M,Valverde MA. TRPV4 channel is involved in the coupling of fluid viscosity changes to epithelial ciliary activityJ Cell BiolYear: 200516886987415753126
5. Andreucci E,Aftimos S,Alcausin M,Haan E,Hunter W,Kannu P,Kerr B,McGillivray G,McKinlay Gardner RJ,Patricelli MG,Sillence D,Thompson E,Zacharin M,Zankl A,Lamande SR,Savarirayan R. TRPV4 related skeletal dysplasias: a phenotypic spectrum highlighted byclinical, radiographic, and molecular studies in 21 new familiesOrphanet J Rare DisYear: 201163721658220
6. Arniges M,Fernandez-Fernandez JM,Albrecht N,Schaefer M,Valverde MA. Human TRPV4 channel splice variants revealed a key role of ankyrin domains in multimerization and traffickingJ Biol ChemYear: 20062811580158616293632
7. Auer-Grumbach M,Olschewski A,Papic L,Kremer H,McEntagart ME,Uhrig S,Fischer C,Frohlich E,Balint Z,Tang B,Strohmaier H,Lochmuller H,Schlotter-Weigel B,Senderek J,Krebs A,Dick KJ,Petty R,Longman C,Anderson NE,Padberg GW,Schelhaas HJ,van Ravenswaaij-Arts CM,Pieber TR,Crosby AH,Guelly C. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2CNat GenetYear: 20104216016420037588
8. Becker D,Blase C,Bereiter-Hahn J,Jendrach M. TRPV4 exhibits a functional role in cell-volume regulationJ Cell SciYear: 20051182435244015923656
9. Bird TD. Charcot-Marie-Tooth Neuropathy Type 2Year: 1993Seattle, USAUniversity of Washingtion
10. Birder L,Kullmann FA,Lee H,Barrick S,de Groat W,Kanai A,Caterina M. Activation of urothelial transient receptor potential vanilloid 4 by 4alpha-phorbol 12,13-didecanoate contributes to altered bladder reflexes in the ratJ Pharmacol Exp TherYear: 200732322723517636010
11. Camacho N,Krakow D,Johnykutty S,Katzman PJ,Pepkowitz S,Vriens J,Nilius B,Boyce BF,Cohn DH. Dominant TRPV4 mutations in nonlethal and lethal metatropic dysplasiaAm J Med Genet AYear: 2010152A1169117720425821
12. Carreno FR,Ji LL,Cunningham JT. Altered central TRPV4 expression and lipid raft association related to inappropriate vasopressin secretion in cirrhotic ratsAm J Physiol Regul Integr Comp PhysiolYear: 2009296R454R46619091909
13. Chen DH,Sul Y,Weiss M,Hillel A,Lipe H,Wolff J,Matsushita M,Raskind W,Bird T. CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 geneNeurologyYear: 2010751968197521115951
14. Cho TJ,Matsumoto K,Fano V,Dai J,Kim OH,Chae JH,Yoo WJ,Tanaka Y,Matsui Y,Takigami I,Monges S,Zabel B,Shimizu K,Nishimura G,Lausch E,Ikegawa S. TRPV4-pathy manifesting both skeletal dysplasia and peripheral neuropathy: a report of three patientsAm J Med Genet AYear: 2012158A79580222419508
15. Chun J,Shin SH,Kang SS. The negative feedback regulation of TRPV4 Ca(2+) ion channel function by its C-terminal cytoplasmic domainCell SignalYear: 2012241918192222735813
16. Cuajungco MP,Grimm C,Oshima K,D'Hoedt D,Nilius B,Mensenkamp AR,Bindels RJ,Plomann M,Heller S. PACSINs bind to the TRPV4 cation channel. PACSIN 3 modulates the subcellular localization of TRPV4J Biol ChemYear: 2006281187531876216627472
17. Dai J,Kim OH,Cho TJ,Schmidt-Rimpler M,Tonoki H,Takikawa K,Haga N,Miyoshi K,Kitoh H,Yoo WJ,Choi IH,Song HR,Jin DK,Kim HT,Kamasaki H,Bianchi P,Grigelioniene G,Nampoothiri S,Minagawa M,Miyagawa SI,Fukao T,Marcelis C,Jansweijer MC,Hennekam RC,Bedeschi F,Mustonen A,Jiang Q,Ohashi H,Furuichi T,Unger S,Zabel B,Lausch E,Superti-Furga A,Nishimura G,Ikegawa S. Novel and recurrent TRPV4 mutations and their association with distinct phenotypes within the TRPV4 dysplasia familyJ Med GenetYear: 20104770470920577006
18. Delany NS,Hurle M,Facer P,Alnadaf T,Plumpton C,Kinghorn I,See CG,Costigan M,Anand P,Woolf CJ,Crowther D,Sanseau P,Tate SN. Identification and characterization of a novel human vanilloid receptor-like protein, VRL-2Physiol GenomicsYear: 2001416517411160995
19. Deng HX,Klein CJ,Yan J,Shi Y,Wu Y,Fecto F,Yau HJ,Yang Y,Zhai H,Siddique N,Hedley-Whyte ET,Delong R,Martina M,Dyck PJ,Siddique T. Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4Nat GenetYear: 20104216516920037587
20. Ding XL,Wang YH,Ning LP,Zhang Y,Ge HY,Jiang H,Wang R,Yue SW. Involvement of TRPV4-NO-cGMP-PKG pathways in the development of thermal hyperalgesia following chronic compression of the dorsal root ganglion in ratsBehav Brain ResYear: 201020819420119948193
21. Earley S,Heppner TJ,Nelson MT,Brayden JE. TRPV4 forms a novel Ca2+ signaling complex with ryanodine receptors and BKCa channelsCirc ResYear: 2005971270127916269659
22. Everaerts W,Nilius B,Owsianik G. The vanilloid transient receptor potential channel TRPV4: from structure to diseaseProg Biophys Mol BiolYear: 201010321719835908
23. Fecto F,Shi Y,Huda R,Martina M,Siddique T,Deng HX. Mutant TRPV4-mediated toxicity is linked to increased constitutive function in axonal neuropathiesJ Biol ChemYear: 2011286172811729121454511
24. Feng S,Rodat-Despoix L,Delmas P,Ong AC. A single amino acid residue constitutes the third dimerization domain essential for the assembly and function of the tetrameric polycystin-2 (TRPP2) channelJ Biol ChemYear: 2011286189941900021474446
25. Fernandes J,Lorenzo IM,Andrade YN,Garcia-Elias A,Serra SA,Fernandez-Fernandez JM,Valverde MA. IP3 sensitizes TRPV4 channel to the mechano- and osmotransducing messenger 5'-6'-epoxyeicosatrienoic acidJ Cell BiolYear: 200818114315518378772
26. Gevaert T,Vriens J,Segal A,Everaerts W,Roskams T,Talavera K,Owsianik G,Liedtke W,Daelemans D,Dewachter I,Van Leuven F,Voets T,De Ridder D,Nilius B. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voidingJ Clin InvestYear: 20071173453346217948126
27. Guler AD,Lee H,Iida T,Shimizu I,Tominaga M,Caterina M. Heat-evoked activation of the ion channel, TRPV4J NeurosciYear: 2002226408641412151520
28. Hartmannsgruber V,Heyken WT,Kacik M,Kaistha A,Grgic I,Harteneck C,Liedtke W,Hoyer J,Kohler R. Arterial response to shear stress critically depends on endothelial TRPV4 expressionPLoS OneYear: 20072e82717786199
29. Hellwig N,Albrecht N,Harteneck C,Schultz G,Schaefer M. Homo- and heteromeric assembly of TRPV channel subunitsJ Cell SciYear: 200511891792815713749
30. Inada H,Procko E,Sotomayor M,Gaudet R. Structural and biochemical consequences of disease-causing mutations in the ankyrin repeat domain of the human TRPV4 channelBiochemistryYear: 2012516195620622702953
31. Jia Y,Wang X,Varty L,Rizzo CA,Yang R,Correll CC,Phelps PT,Egan RW,Hey JA. Functional TRPV4 channels are expressed in human airway smooth muscle cellsAm J Physiol Lung Cell Mol PhysiolYear: 2004287L272L27815075247
32. Kang SS. The mutation of transient receptor potential vanilloid 4 (TRPV4) cation channel in human diseasesMutagenesisYear: 2012CroatiaInTech in press.
33. Kim KS,Shin DH,Nam JH,Park KS,Zhang YH,Kim WK,Kim SJ. Functional Expression of TRPV4 Cation Channels in Human Mast Cell Line (HMC-1)Korean J Physiol PharmacolYear: 20101441942521311684
34. Krakow D,Vriens J,Camacho N,Luong P,Deixler H,Funari TL,Bacino CA,Irons MB,Holm IA,Sadler L,Okenfuss EB,Janssens A,Voets T,Rimoin DL,Lachman RS,Nilius B,Cohn DH. Mutations in the gene encoding the calcium-permeable ion channel TRPV4 produce spondylometaphyseal dysplasia, Kozlowski type and metatropic dysplasiaAm J Hum GenetYear: 20098430731519232556
35. Lamande SR,Yuan Y,Gresshoff IL,Rowley L,Belluoccio D,Kaluarachchi K,Little CB,Botzenhart E,Zerres K,Amor DJ,Cole WG,Savarirayan R,McIntyre P,Bateman JF. Mutations in TRPV4 cause an inherited arthropathy of hands and feetNat GenetYear: 2011431142114621964574
36. Landoure G,Zdebik AA,Martinez TL,Burnett BG,Stanescu HC,Inada H,Shi Y,Taye AA,Kong L,Munns CH,Choo SS,Phelps CB,Paudel R,Houlden H,Ludlow CL,Caterina MJ,Gaudet R,Kleta R,Fischbeck KH,Sumner CJ. Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2CNat GenetYear: 20104217017420037586
37. Lee EJ,Shin SH,Hyun S,Chun J,Kang SS. The mudulation of TRPV4 channel activity through its 824 Ser residue phosphorylation by SGK1Animal Cells Syst (Seoul)Year: 20101499114
38. Lee EJ,Shin SH,Hyun S,Chun J,Kang SS. Mutation of a putative S-nitrosylation site of TRPV4 protein facilitates the channel activatesAnimal Cells Syst (Seoul)Year: 2011159510621837266
39. Lewis R,Feetham CH,Barrett-Jolley R. Cell volume regulation in chondrocytesCell Physiol BiochemYear: 2011281111112222179000
40. Li J,Kanju P,Patterson M,Chew WL,Cho SH,Gilmour I,Oliver T,Yasuda R,Ghio A,Simon SA,Liedtke W. TRPV4-mediated calcium influx into human bronchial epithelia upon exposure to diesel exhaust particlesEnviron Health PerspectYear: 201111978479321245013
41. Loukin S,Su Z,Kung C. Increased basal activity is a key determinant in the severity of human skeletal dysplasia caused by TRPV4 mutationsPLoS OneYear: 20116e1953321573172
42. Loukin S,Su Z,Zhou X,Kung C. Forward genetic analysis reveals multiple gating mechanisms of TRPV4J Biol ChemYear: 2010a285198841989020424166
43. Loukin S,Zhou X,Su Z,Saimi Y,Kung C. Wild-type and brachyolmia-causing mutant TRPV4 channels respond directly to stretch forceJ Biol ChemYear: 2010b285271762718120605796
44. Ma X,Cheng KT,Wong CO,O'Neil RG,Birnbaumer L,Ambudkar IS,Yao X. Heteromeric TRPV4-C1 channels contribute to store-operated Ca(2+) entry in vascular endothelial cellsCell CalciumYear: 20115050250921930300
45. Masuyama R,Mizuno A,Komori H,Kajiya H,Uekawa A,Kitaura H,Okabe K,Ohyama K,Komori T. Calcium/calmodulin-signaling supports TRPV4 activation in osteoclasts and regulates bone massJ Bone Miner ResYear: 2012271708172122492541
46. Masuyama R,Vriens J,Voets T,Karashima Y,Owsianik G,Vennekens R,Lieben L,Torrekens S,Moermans K,Vanden Bosch A,Bouillon R,Nilius B,Carmeliet G. TRPV4-mediated calcium influx regulates terminal differentiation of osteoclastsCell MetabYear: 2008825726518762026
47. McEntagart M. TRPV4 axonal neuropathy spectrum disorderJ Clin NeurosciYear: 20121992793322617546
48. Mizoguchi F,Mizuno A,Hayata T,Nakashima K,Heller S,Ushida T,Sokabe M,Miyasaka N,Suzuki M,Ezura Y,Noda M. Transient receptor potential vanilloid 4 deficiency suppresses unloading-induced bone lossJ Cell PhysiolYear: 2008216475318264976
49. Muramatsu S,Wakabayashi M,Ohno T,Amano K,Ooishi R,Sugahara T,Shiojiri S,Tashiro K,Suzuki Y,Nishimura R,Kuhara S,Sugano S,Yoneda T,Matsuda A. Functional gene screening system identified TRPV4 as a regulator of chondrogenic differentiationJ Biol ChemYear: 2007282321583216717804410
50. Nedungadi TP,Carreno FR,Walch JD,Bathina CS,Cunningham JT. Region-specific changes in transient receptor potential vanilloid channel expression in the vasopressin magnocellular system in hepatic cirrhosis-induced hyponatraemiaJ NeuroendocrinolYear: 20122464265222188460
51. Nemec SF,Cohn DH,Krakow D,Funari VA,Rimoin DL,Lachman RS. The importance of conventional radiography in the mutational analysis of skeletal dysplasias (the TRPV4 mutational family)Pediatr RadiolYear: 201242152321863289
52. Nilius B,Owsianik G. Channelopathies converge on TRPV4Nat GenetYear: 2010429810020104247
53. Nilius B,Vriens J,Prenen J,Droogmans G,Voets T. TRPV4 calcium entry channel: a paradigm for gating diversityAm J Physiol Cell PhysiolYear: 2004286C195C20514707014
54. Nishimura G,Dai J,Lausch E,Unger S,Megarbane A,Kitoh H,Kim OH,Cho TJ,Bedeschi F,Benedicenti F,Mendoza-Londono R,Silengo M,Schmidt-Rimpler M,Spranger J,Zabel B,Ikegawa S,Superti-Furga A. Spondylo-epiphyseal dysplasia, Maroteaux type (pseudo-Morquio syndrome type 2), and parastremmatic dysplasia are caused by TRPV4 mutationsAm J Med Genet AYear: 2010152A1443144920503319
55. Obeidat M,Wain LV,Shrine N,Kalsheker N,Soler Artigas M,Repapi E,Burton PR,Johnson T,Ramasamy A,Zhao JH,Zhai G,Huffman JE,Vitart V,Albrecht E,Igl W,Hartikainen AL,Pouta A,Cadby G,Hui J,Palmer LJ,Hadley D,McArdle WL,Rudnicka AR,Barroso I,Loos RJ,Wareham NJ,Mangino M,Soranzo N,Spector TD,Glaser S,Homuth G,Volzke H,Deloukas P,Granell R,Henderson J,Grkovic I,Jankovic S,Zgaga L,Polasek O,Rudan I,Wright AF,Campbell H,Wild SH,Wilson JF,Heinrich J,Imboden M,Probst-Hensch NM,Gyllensten U,Johansson A,Zaboli G,Mustelin L,Rantanen T,Surakka I,Kaprio J,Jarvelin MR,Hayward C,Evans DM,Koch B,Musk AW,Elliott P,Strachan DP,Tobin MD,Sayers I,Hall IP. A comprehensive evaluation of potential lung function associated genes in the SpiroMeta general population samplePLoS OneYear: 20116e1938221625484
56. Phelps CB,Wang RR,Choo SS,Gaudet R. Differential regulation of TRPV1, TRPV3, and TRPV4 sensitivity through a conserved binding site on the ankyrin repeat domainJ Biol ChemYear: 201028573174019864432
57. Ramadass R,Becker D,Jendrach M,Bereiter-Hahn J. Spectrally and spatially resolved fluorescence lifetime imaging in living cells: TRPV4-microfilament interactionsArch Biochem BiophysYear: 2007463273617374521
58. Shin SH,Lee EJ,Hyun S,Chun J,Kim Y,Kang SS. Phosphorylation on the Ser 824 residue of TRPV4 prefers to bind with F-actin than with microtubules to expand the cell surface areaCell SignalYear: 20122464165122101010
59. Sonkusare SK,Bonev AD,Ledoux J,Liedtke W,Kotlikoff MI,Heppner TJ,Hill-Eubanks DC,Nelson MT. Elementary Ca2+ signals through endothelial TRPV4 channels regulate vascular functionScienceYear: 201233659760122556255
60. Strotmann R,Harteneck C,Nunnenmacher K,Schultz G,Plant TD. OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarityNat Cell BiolYear: 2000269570211025659
61. Strotmann R,Schultz G,Plant TD. Ca2+-dependent potentiation of the nonselective cation channel TRPV4 is mediated by a C-terminal calmodulin binding siteJ Biol ChemYear: 2003278265412654912724311
62. Suzuki M,Hirao A,Mizuno A. Microtubule-associated [corrected] protein 7 increases the membrane expression of transient receptor potential vanilloid 4 (TRPV4)J Biol ChemYear: 2003a278514485145314517216
63. Suzuki M,Mizuno A,Kodaira K,Imai M. Impaired pressure sensation in mice lacking TRPV4J Biol ChemYear: 2003b278226642266812692122
64. Tabuchi K,Suzuki M,Mizuno A,Hara A. Hearing impairment in TRPV4 knockout miceNeurosci LettYear: 200538230430815925108
65. Tian W,Fu Y,Garcia-Elias A,Fernandez-Fernandez JM,Vicente R,Kramer PL,Klein RF,Hitzemann R,Orwoll ES,Wilmot B,McWeeney S,Valverde MA,Cohen DM. A loss-of-function nonsynonymous polymorphism in the osmoregulatory TRPV4 gene is associated with human hyponatremiaProc Natl Acad Sci USAYear: 2009106140341403919666518
66. Unger S,Lausch E,Stanzial F,Gillessen-Kaesbach G,Stefanova I,Di Stefano CM,Bertini E,Dionisi-Vici C,Nilius B,Zabel B,Superti-Furga A. Fetal akinesia in metatropic dysplasia: The combined phenotype of chondrodysplasia and neuropathy?Am J Med Genet AYear: 2011155A2860286421964829
67. Vennekens R,Owsianik G,Nilius B. Vanilloid transient receptor potential cation channels: an overviewCurr Pharm DesYear: 200814183118220815
68. Verma P,Kumar A,Goswami C. TRPV4-mediated channelopathiesChannels (Austin)Year: 2010431932820676052
69. Voets T,Prenen J,Vriens J,Watanabe H,Janssens A,Wissenbach U,Bodding M,Droogmans G,Nilius B. Molecular determinants of permeation through the cation channel TRPV4J Biol ChemYear: 2002277337043371012093812
70. Vriens J,Owsianik G,Fisslthaler B,Suzuki M,Janssens A,Voets T,Morisseau C,Hammock BD,Fleming I,Busse R,Nilius B. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endotheliumCirc ResYear: 20059790891516179585
71. Vriens J,Watanabe H,Janssens A,Droogmans G,Voets T,Nilius B. Cell swelling, heat, and chemical agonists use distinct pathways for the activation of the cation channel TRPV4Proc Natl Acad Sci USAYear: 200410139640114691263
72. Wang Y,Fu X,Gaiser S,Kottgen M,Kramer-Zucker A,Walz G,Wegierski T. OS-9 regulates the transit and polyubiquitination of TRPV4 in the endoplasmic reticulumJ Biol ChemYear: 2007282365613657017932042
73. Watanabe H,Davis JB,Smart D,Jerman JC,Smith GD,Hayes P,Vriens J,Cairns W,Wissenbach U,Prenen J,Flockerzi V,Droogmans G,Benham CD,Nilius B. Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivativesJ Biol ChemYear: 2002a277135691357711827975
74. Watanabe H,Vriens J,Suh SH,Benham CD,Droogmans G,Nilius B. Heat-evoked activation of TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial cellsJ Biol ChemYear: 2002b277470444705112354759
75. Watanabe H,Vriens J,Prenen J,Droogmans G,Voets T,Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channelsNatureYear: 200342443443812879072
76. Wegierski T,Hill K,Schaefer M,Walz G. The HECT ubiquitin ligase AIP4 regulates the cell surface expression of select TRP channelsEMBO JYear: 2006255659566917110928
77. Yoshida T,Inoue R,Morii T,Takahashi N,Yamamoto S,Hara Y,Tominaga M,Shimizu S,Sato Y,Mori Y. Nitric oxide activates TRP channels by cysteine S-nitrosylationNat Chem BiolYear: 2006259660716998480
78. Zhu G,Gulsvik A,Bakke P,Ghatta S,Anderson W,Lomas DA,Silverman EK,Pillai SG. Association of TRPV4 gene polymorphisms with chronic obstructive pulmonary diseaseHum Mol GenetYear: 2009182053206219279160
79. Zimon M,Baets J,Auer-Grumbach M,Berciano J,Garcia A,Lopez-Laso E,Merlini L,Hilton-Jones D,McEntagart M,Crosby AH,Barisic N,Boltshauser E,Shaw CE,Landoure G,Ludlow CL,Gaudet R,Houlden H,Reilly MM,Fischbeck KH,Sumner CJ,Timmerman V,Jordanova A,Jonghe PD. Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathiesBrainYear: 20101331798180920460441

Article Categories:
  • Review

Keywords: genetic diseases, inborn, osteochondrodysplasias, osteogenesis, phosphorylation, TRPV cation channels.

Previous Document:  Estradiol regulates miR-135b and mismatch repair gene expressions via estrogen receptor-? in colorec...
Next Document:  The facial nerve canal in patients with Bell's palsy: an investigation by high-resolution computed t...